omniture
信达生物

Latest News

Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress

SUZHOU, China, March 30, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company"...

2020-03-31 00:08 1735

Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China

SUZHOU, China, March 26, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company"...

2020-03-26 07:00 1954

Innovent Biologics Announces First Patient Dosed in the Pivotal Registrational Trial of Pemigatinib in Patients with Advanced Cholangiocarcinoma in China

SUZHOU, China, March 4, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company")...

2020-03-04 08:00 3835

Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

SUZHOU, China, Jan. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company")...

2020-01-14 08:00 12399

Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

SUZHOU, China, Jan. 13, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2020-01-13 12:42 11394

Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-01-08 08:00 6929

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2019-12-10 16:00 1243

Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China

SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") ...

2019-12-06 08:00 9615

Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly

SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (01801.HK), a multinational biophar...

2019-12-02 09:37 4027

Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)

SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2019-11-28 12:10 1644

Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China

SUZHOU, China, Nov. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company")...

2019-11-27 07:50 1037

Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

SUZHOU, China, Oct. 21, 2019 /PRNewswire/ --  Innovent Biologics, Inc. ("Innovent" or "the Company"...

2019-10-21 08:00 755

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

SUZHOU, China and LONDON, Oct. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX...

2019-10-10 15:55 6167

Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million

SUZHOU, China, Oct. 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") ...

2019-10-04 16:11 1417

Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO

SUZHOU, China, Sept. 20, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-09-20 14:30 7399

Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-09-19 16:36 7060
1234